Showing 1461-1470 of 5771 results for "".
- Iveric Bio Announces 24-Month Topline Results from Phase 3 Study of Izervay for Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-24-month-topline-results-from-phase-3-study-of-izervay-for-geographic-atrophy/2481834/Astellas Pharma, the parent company of Iveric Bio, announced positive 24-month topline results from the phase 3 GATHER2 clinical trial evaluating the efficacy and safety of Izervay (avacincaptad pegol intravitreal solution), a recently approved complement C5 inhibitor for the treatment of ge
- Ace Vision Group to Present Nine New Sets of Scientific Data Focused on Laser Scleral Microporation at the ESCRS Annual Meetinghttps://modernod.com/news/ace-vision-group-to-present-nine-new-sets-of-scientific-data-focused-on-laser-scleral-microporation-at-the-escrs-annual-meeting/2481820/Ace Vision Group (AVG) announced it will present nine sets of research on the effectiveness of Laser Scleral Microporation (LSM) at the annual congress of the European Society of Cataract and Refractive Surgeons (ESCRS). LSM is an ultra-minimally invasive procedure with a nov
- Eye Care Charity Orbis Announces New Partnership with Heidelberg Engineeringhttps://modernod.com/news/eye-care-charity-orbis-announces-new-partnership-with-heidelberg-engineering/2481817/Orbis announced a new partnership with Heidelberg Engineering in which Heidelburg will fund crucial teaching opportunities and research—focusing on training eye care professionals around the world via Cybersight (Orbis’s telemedicine and e-learning p
- Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Devicehttps://modernod.com/news/myra-vision-announces-first-in-human-use-of-its-calibreye-glaucoma-drainage-device/2481816/Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label
- ESCRS Releases the 2022-2023 EUREQUO Annual Reporthttps://modernod.com/news/escrs-releases-the-2022-2023-eurequo-annual-report/2481801/The European Society of Cataract & Refractive Surgeons (ESCRS) has released the 2022-2023 EUREQUO annual report. ESCRS is marking the 15th anniversary of the establishment of the EUREQUO Registry with the announcement that the cataract and refractive database has grown to more than 4 mil
- Apellis Announces Corporate Restructuring and Workforce Reductionhttps://modernod.com/news/apellis-announces-corporate-restructuring-and-workforce-reduction/2481797/Apellis Pharmaceuticals announced a corporate restructuring that it says will cut costs and position the company for long-term success. As part of the restructuring, Apellis said it is reducing headcount by approximately 225 employees, or about 25% of the current wo
- Atsena Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-announces-first-patient-dosed-in-phase-12-clinical-trial-of-atsn-201-for-the-treatment-of-x-linked-retinoschisis/2481796/Atsena Therapeutics announced the first patient has been dosed in the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 uses AAV.SPR, the company’s novel spreading c
- Neurophth Announces First Patient Dosed in Phase 1/2 Clinical Trial of Second Gene Therapyhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-12-clinical-trial-of-second-gene-therapy/2481786/Neurophth Therapeutics announced that the first patient has been dosed in the international multi-region, multicenter phase 1/2 clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON). Neurophth is conducting a phase 1/2, mu
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- ViGeneron Announces EMA Approval of Clinical Trial Application for VG901, a Gene Therapy to Treat RPhttps://modernod.com/news/vigeneron-announces-ema-approval-of-clinical-trial-application-for-vg901-a-gene-therapy-to-treat-retinitis-pigmentosa/2481784/ViGeneron announced that the European Medicines Agency (EMA) has approved the clinical trial application for VG901, a gene therapy to treat CNGA1-associated retinitis pigmentosa (RP). VG901 uses vgAAV, ViGeneron's proprietary adeno-associated virus (AAV) vector to deliver the CNGA1